Compare Abeona Therapeutics Inc (ABEO) vs Air Products & Chemicals, Inc. (APD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Air Products & Chemicals, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.88B). The key difference: Air Products & Chemicals, Inc. is far larger — about 163.5× Abeona Therapeutics Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.34% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | APD | |
|---|---|---|
Market Cap | $421.19M | $68.88B |
Sector | Health | Basic Materials |
52-Week High | $7.45 | $314.19 |
52-Week Low | $4.17 | $230.42 |
Enterprise Value | $276.10M | $86.06B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Air Products and Chemicals (APD) trades at $304.01, down 1.35% with strong technical momentum and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though recent profitability metrics show negative net income margin and ROE. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance, while analyst consensus remains strongly positive with a $346 price target representing 14% upside potential.
The outlook remains constructive given earnings momentum and strategic contract wins, but investors face risks from elevated valuation multiples and recent negative profitability. The stock's technical strength and institutional support provide near-term catalysts, though margin recovery and debt management will be critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →
